Celldex Therapeutics, Inc. (CLDX)

Market Cap	2.03B
Revenue (ttm)	1.08M
Net Income (ttm)	-105.99M
Shares Out	47.10M
EPS (ttm)	-2.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,106
Open	43.81
Previous Close	43.71
Day's Range	42.09 - 44.35
52-Week Range	19.85 - 48.40
Beta	2.28
Analysts	Buy
Price Target	65.62 (+52.29%)
Earnings Date	Feb 27, 2023

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 10, 2008
• Employees: 132
• Stock Exchange: NASDAQ
• Ticker Symbol: CLDX

Financial Performance

In 2021, CLDX's revenue was $4.65 million, a decrease of -37.30% compared to the previous year's $7.42 million. Losses were -$70.51 million, 18.0% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $65.62, which is an increase of 52.29% from the latest price.

Price Target

$65.62

(52.29% upside)

Analyst Consensus: Buy